Cinq ans d'expérience sur le phosphate 3,4-diaminopyridine dans le syndrome de Lambert-Eaton: rapports de cas.

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar du membre

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 5019
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 10 Firefox
Genre :
Zodiaque : Lion
Âge : 61
Contact :
France

Cinq ans d'expérience sur le phosphate 3,4-diaminopyridine dans le syndrome de Lambert-Eaton: rapports de cas.

Message par Pboulanger » 20 oct. 2017 07:57

:hi:

:arrow: Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/28930822

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Image

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports.
Portaro S1, Brizzi T, Sinicropi S, Cacciola A, De Cola MC, Bramanti A, Milardi D, Lupica A, Bramanti P, Toscano A, Rodolico C.
Medicine (Baltimore). 2017 Sep;96(38):e7839. doi: 10.1097/MD.0000000000007839.

Abstract
  • RATIONALE:

    To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert-Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids.
  • PATIENT CONCERNS:

    Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (QMG) and activities of daily living scales, and autonomic nervous system involvement evaluation.
  • OUTCOMES:

    Five out of 7 patients presented a clinical improvement persisting at last 5-year follow-up; 2 out of them improved taking only 3,4-DAPP at the maximal dosage, whereas the remaining received concomitant medications, such as prednisone and azathioprine. However, the clinical amelioration was not statistically significant. No one of the patients reported severe adverse events, except one, complaining of transient chin and perioral paresthesias. A significant association between QMG and the type of pharmacological drugs therapy (P = .028) emerged. Indeed, we observed an improvement of the clinical condition in all 3 subjects treated with 3,4-DAPP and prednisone.
  • CONCLUSIONS:

    In this study, we confirm 3,4-DAPP treatment efficacy on muscle strength, but minor evidence of drug effectiveness have been demonstrated on the autonomic nervous system involvement and on the deep tendon reflexes reappearance, a part from patients who received 3,4-DAPP associated to prednisone.
Lien Google traduction https://translate.google.fr/translate?s ... t=&act=url
Message de : Pboulanger  un membre de l'équipe technique
Nous utilisons un service automatique de traduction fourni par YANDEX.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
Amicalement,
Image

Répondre

Retourner vers « Informations »